Nicox S.A. ( COX.PA) Stock. Should you Buy or Sell? $ 2.02
0.06 (2.88 %)
Nicox S.A. Analysis
Updated on 10-09-2022
| Symbol |
COX.PA |
| Price |
$2.02 |
| Beta |
1.429 |
| Volume Avg. |
$41.44 thousand |
| Market Cap |
$87.31 M |
| 52 Week Range |
$1.594 - $3.72 |
Nicox S.A. opened the day at $2.02 which is +'2.88 % on yesterday's close.
Nicox S.A. has a 52 week high of $3.72 and 52 week low of $1.594, which is a difference of $2.126.
We like to see positive, upward trending shares, preferably with momentum.
Market capitalization is $87.31 M and total net profit is $8583000 which means the company is trading at 10.17 times profit to market capitalization. Theoretically, if you were to buy Nicox S.A. for $87.31 M, it would take 15 years to get your money back. Nicox S.A. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
1 D | All
Financials
Nicox S.A. Stock Forecast - Is Nicox S.A. a Buy or Sell?
| DCF Score | | Strong Buy |
| ROE Score | | Neutral |
| ROA Score | | Neutral |
| DE Score | | Neutral |
| PE Score | | Strong Sell |
| PB Score | | Strong Buy |
| Overall Recommendation | | Buy |
Growth and Value
| PE Ratio |
-1.655 |
| Dividend Yiel |
0.000 |
| Net Profit Margin |
-23.819 |
Valuing Nicox S.A.
| Price Book Value Ratio |
0.390 |
Price To Book Ratio |
0.390 |
| Price To Sales Ratio |
39.424 |
Price Earnings Ratio |
-1.655 |
How liquid is Nicox S.A.
| Current Ratio |
5.967 |
| Quick Ratio |
5.246 |
Debt
| Debt Ratio |
0.341 |
Debt Equity Ratio |
0.517 |
| Long Term Debt To Capitalization |
0.219 |
Total Debt To Capitalization |
0.222 |
Latest news about Nicox S.A.
About Nicox S.A.
CEO : Mr. Michele Garufi
Sector : Healthcare
Industry : Biotechnology
Website : https://www.nicox.com
Description :
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.
